Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - protective
8
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Amino Acid Substitutions Mutants of Anthrax
Protective
Antigen, Lethal Factor, and Edema Factor
Anthrax toxin proteins available for licensing. Bacillus anthracis hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided): PA.
Protective
antigen, wild type PA-3M (PA D683A, L685E, Y688K) PA-3M Cys PA-U7 PA...
Published: 10/28/2024
|
Inventor(s):
Stephen Leppla
Keywords(s):
Acid
,
AMINO
,
Anthrax
,
ANTIGEN
,
Edema
,
factor
,
Lethal
,
Listed LPM Ano as of 4/15/2015
,
Mutants
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
Protective
,
RM
,
SUBSTITUTIONS
,
VJXXXX
,
WIXXXX
Category(s):
Collaboration Sought > Licensing
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
Chlamydial Vaccine Technologies
The National Institute of Allergy and Infectious Diseases has invented three chlamydial vaccine technologies, which have shown promising preclinical efficacy. Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection. If left untreated, chlamydia infection can lead to pelvic inflammatory disease and infertility. Chlamydia...
Published: 10/28/2024
|
Inventor(s):
Laszlo Kari
,
Deborah Crane
,
Harlan Caldwell
Keywords(s):
Against
,
Attenuated
,
-Attenuated
,
Bacterial strains
,
Blinding
,
Chlamydia
,
DA3XXX
,
DC4XXX
,
DCXXXX
,
DD1XXX
,
DDXXXX
,
DISEASES
,
Human
,
Immunogenic
,
Listed LPM Stansberry as of 4/15/2015
,
Live
,
Model
,
MULTIPLE
,
NON
,
Patent Category - Biotechnology
,
Plasmid-deficient
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
primate
,
Protective
,
RM
,
SAFE
,
Sexually
,
Strain
,
Trachoma
,
TRACHOMATIS
,
Transmitted
,
UBXXXX
,
Vaccine
,
VJXXXX
,
WIXXXX
,
WNXXXX
Category(s):
Collaboration Sought > Licensing
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
,
TherapeuticArea > Rare / Neglected Diseases
,
Application > Diagnostics
Linear Epitopes of Anthrax Toxin
Protective
Antigen for Development of a Peptide Vaccine
Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis
protective
antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection...
Published: 10/28/2024
|
Inventor(s):
Conrad Quinn
,
Jan Pohl
,
Pavel Svoboda
,
Shannon Dalton
,
Jarad Schiffer
,
Stephen Soroka
,
Vera Semenova
Keywords(s):
Anthrax
,
ANTIGEN
,
Bacillus
,
biosecurity
,
Bioterrism
,
Bio-terrorism
,
Bioterrorist
,
BioWarfare
,
CDC Docket Import
,
CDC Docket Import CDC Prosecuting
,
DC1XXX
,
DC4XXX
,
DCXXXX
,
Development
,
DXXXXX
,
Epitopes
,
LINEAR
,
OID-NCIRD-DBD
,
PA
,
Peptide
,
Protection
,
Protective
,
toxin
,
Vaccine
Category(s):
Collaboration Sought > Licensing
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease
Engineered Anthrax Toxin Variants that Target Cancer
This technology describes the use of novel mutated anthrax
protective
antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins...
Published: 10/28/2024
|
Inventor(s):
Stephen Leppla
,
Damilola Phillips
,
Clinton Leysath
Keywords(s):
Anthrax
,
ANTIGEN
,
CB1BXX
,
CB1XXX
,
CBXXXX
,
COMPLEMENTARY
,
CXXXXX
,
ENGINEERED
,
exclusively
,
FORM
,
Octamers
,
Protective
,
That
,
toxin
,
VARIANTS
Category(s):
Collaboration Sought > Collaboration
,
TherapeuticArea > Oncology
,
Application > Therapeutics
,
TherapeuticArea > Immunology
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 10/28/2024
|
Inventor(s):
Stephen Leppla
,
Shihui Liu
,
Thomas Bugge
,
Diane Peters
,
Jie Liu
,
Alexander Wein
,
Kuang-Hua Chen
,
Christopher Bachran
,
Damilola Phillips
,
Henning Hansen
,
Sarah Arnett
,
Clinton Leysath
Keywords(s):
Against
,
AMOUNTS
,
Anthrax
,
AnthraxToxins
,
ANTIGEN
,
B
,
CA1BXX
,
CB1AXX
,
CB1BXX
,
CB1XXX
,
CB3CXX
,
CBXXXX
,
Cells
,
Cell-Surface
,
CMG2
,
COMPLEMENTARY
,
CONTAIN
,
Containing
,
CXXXXX
,
Cytolethal
,
Distending
,
EFFICACY
,
Efficient
,
ENGINEERED
,
exclusively
,
Exploiting
,
FELINE
,
FELINE Leukemia
,
FORM
,
Fusion
,
fusion proteins
,
Having
,
High
,
IC2-PA
,
Identifying
,
Improved
,
Leppla
,
Listed LPM McCue as of 4/15/2015
,
MARKER
,
Metallo...
,
MULTIMERIC
,
Mutated
,
Nature
,
Octamers
,
Patent Category - Biotechnology
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
Protective
,
Protein
,
proteins
,
SOLID
,
SPECIFICALLY
,
Specificity
,
Strong
,
TARGET
,
Targeting
,
That
,
THERAPY
,
toxin
,
TOXINS
,
tumor
,
Types
,
UAXXXX
,
VARIANTS
,
VASCULATURE
,
VETERINARY
Category(s):
Collaboration Sought > Collaboration
,
Application > Therapeutics
,
TherapeuticArea > Oncology
,
TherapeuticArea > Immunology
,
Application > Diagnostics
,
TherapeuticArea > Rare / Neglected Diseases
Recombinant Modified
Bacillus anthracis
Protective
Antigen for Use in Vaccines
This invention relates to improved methods of preparing Bacillus anthracis
protective
antigen (PA) for use in vaccines. PA is a secreted, non-toxic protein with a molecular weight of 83 KDa. PA is a major component of the currently licensed human vaccine (Anthrax Vaccine Adsorbed, AVA). Although the licensed human vaccine has been shown to be effective...
Published: 10/28/2024
|
Inventor(s):
John Robbins
,
Stephen Leppla
,
Rachel Schneerson
,
M Rosovitz
Keywords(s):
Anthrax
,
ANTIGEN
,
Chromosome 18 ring
,
Chymotrypsin-Sensitive
,
CREATION
,
Cutaneous anthrax
,
DAXXXX
,
DBXXXX
,
DC4XXX
,
DC6XXX
,
DCXXXX
,
DDXXXX
,
DELETIONS
,
DXXXXX
,
Furin-Cleavage...
,
Loop
,
MOLECULE
,
Protective
,
R 18
,
recombinant
,
rPA
,
STABLE
,
UAXXXX
Category(s):
Application > Diagnostics
,
TherapeuticArea > Rare / Neglected Diseases
,
Application > Research Materials
,
TherapeuticArea > Infectious Disease
,
Application > Therapeutics
,
Application > Vaccines
Monoclonal Antibodies that Neutralize
B. anthracis
Protective
Antigen (PA), Lethal Factor (LF) and Edema Factor (EF)
Anthrax, whether resulting from natural or bioterrorist-associated exposure, is a constant threat to human health. The lethality of anthrax is primarily the result of the effects of anthrax toxin, which has 3 components: a receptor-binding protein known as "
protective
antigen" (PA) and 2 catalytic proteins known as "lethal factor" (LF) and "edema factor"...
Published: 10/28/2024
|
Inventor(s):
Stephen Leppla
,
Suzanne Emerson
,
Robert Purcell
,
Mahtab Moayeri
,
Zhaochun Chen
Keywords(s):
Anthrax
,
antibodies
,
ANTIBODY
,
ANTIGEN
,
Chimpaneze
,
DA3XXX
,
DAXXXX
,
DB3XXX
,
DBXXXX
,
DC4XXX
,
DCXXXX
,
DDXXXX
,
DXXXXX
,
Edema
,
FACTORS
,
Lethal
,
monoclonal
,
Neutralize
,
Neutralizes
,
PA
,
Protective
,
That
,
toxin
,
UAXXXX
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
Application > Research Materials
,
Application > Diagnostics
,
Application > Vaccines
,
TherapeuticArea > Rare / Neglected Diseases
,
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
Cervical Spine Protection Device (CSPD) for American Football Players
PAGE TITLE Overview PAGE SUMMARY Researchers in the Department of Mechanical Engineering and Mechanics at Drexel University have developed a cervical spine protection device (CSPD) for reducing neck injuries in high impact sports. There is a demonstrated need for better protection of the cervical spine to prevent spinal cord injury, compression...
Published: 7/22/2024
|
Inventor(s):
Sorin Siegler
,
Mary Milone
,
Yoganand Ghati
Keywords(s):
Orthopedic
,
Protective
,
Sports medicine
Category(s):
Medical Devices & Diagnostics
,
Medical Devices & Diagnostics > MDD: Implantable/Prosthetic Devices
,
Medical Devices & Diagnostics > MDD: Therapeutic Devices